WP
GMAB icon

Woodline Partners’s Genmab GMAB Stock Holding History

Woodline Partners’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-369,188
Closed -$11.4M – 1085
2025
Q4 		$11.4M Sell
369,188
-89,988
-20% -$2.8M 0.04% 428
2025
Q3 		$14.1M Sell
459,176
-34,330
-7% -$837K 0.07% 353
2025
Q2 		$10.2M Buy
+493,506
New +$10.1M 0.05% 430

Other funds holding GMAB

OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Woodline Partners's GMAB Position: Q1 2026 in Review

Woodline Partners sold out of Genmab (GMAB) in Q1 2026, closing a stake of 369,188 shares — an estimated $11.4M sold.

Woodline Partners first reported a position in GMAB in Q2 2025 and held it in 3 quarters. The position peaked at $14.1M in Q3 2025. 272 funds tracked by Wall St. Rank hold GMAB as of Q1 2026.

  • Woodline Partners reported no remaining Genmab position as of Q1 2026 after selling out during the quarter.
  • Woodline Partners sold 369,188 Genmab shares in Q1 2026, an estimated $11.4M.
  • Woodline Partners first reported a position in Genmab in Q2 2025 and held it in 3 quarters.
  • Woodline Partners's Genmab position peaked at $14.1M in Q3 2025.
  • 272 funds tracked by Wall St. Rank held Genmab as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.